14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
HCHL vs AARD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Aardvark Therapeutics, Inc. (AARD) captures the overall head-to-head institutional edge over Happy City Holdings Limited Class A (HCHL) on higher Unified Composite conviction (46.4/100 HOLD vs. 45.1/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while HCHL wins 3–2 across the 6-pillar growth and valuation breakdown. HCHL trades at $3.96 (N/M Forward P/E, -101.6% operating margin) versus AARD at $1.00 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: AARD earns the overall head-to-head edge with a stronger Unified Composite Score (46.4/100 HOLD vs. HCHL 45.1/100 HOLD) and 4.01β · 285% Vol risk profile, whereas HCHL leads top-line expansion (-45.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: HCHL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.6); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HCHL vs AARD. Trailing 12-month operating profitability (HCHL -101.6% vs AARD 0.0%) and valuation multiples (HCHL N/M vs AARD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $19.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ HCHL vs AARD Key Questions & Quantitative Answers
As of Nov 19, 2026, Aardvark Therapeutics, Inc. (AARD) captures the overall head-to-head institutional edge over Happy City Holdings Limited Class A (HCHL) on higher Unified Composite conviction (46.4/100 HOLD vs. 45.1/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while HCHL wins 3–2 across the 6-pillar growth and valuation breakdown. HCHL trades at $3.96 (N/M Forward P/E, -101.6% operating margin) versus AARD at $1.00 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: AARD earns the overall head-to-head edge with a stronger Unified Composite Score (46.4/100 HOLD vs. HCHL 45.1/100 HOLD) and 4.01β · 285% Vol risk profile, whereas HCHL leads top-line expansion (-45.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HCHL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.6); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HCHL leads the Growth & Scale pillar: HCHL posts -45.7% YoY revenue growth and +0.0% YoY earnings growth on $6.8M TTM revenue (12.6% gross margin, -101.6% operating margin), compared with AARD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, HCHL generates $6.8M in USD-normalized revenue versus N/A for AARD. In operating R&D and SG&A reinvestment, HCHL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AARD.
HCHL screens cheaper on headline valuation multiples. HCHL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.6x EV/Revenue (-24.5% EBITDA margin), whereas AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HCHL (-173.0% ROE) versus AARD (-66.0% ROE) capital efficiency.
In options market volatility and institutional positioning, HCHL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.84β · 94% Vol realized risk). By comparison, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 285% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.